Accountability in patient adherence.
accountability
adherence
patient behavior
self-determination theory
self-efficacy
Journal
Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748
Informations de publication
Date de publication:
2019
2019
Historique:
received:
23
04
2019
accepted:
27
08
2019
entrez:
1
10
2019
pubmed:
1
10
2019
medline:
1
10
2019
Statut:
epublish
Résumé
The accountability inherent in the social interaction between a patient and healthcare provider affects patients' motivation to adhere to treatment. To characterize the role of accountability as a tool to improve self-efficacy and self-management and thereby promote patients' adherence to treatment, a measure of accountability is needed. To develop and test the validity, reliability, and sensitivity of a new outcome measure designed to assess accountability. The accountability measurement tool was developed from the literature, expert consultation, and focus groups. A focus group and three pilot studies were performed both in clinic and through an online crowdsourcing platform. Principal Component Analysis evaluated constructs, and Cronbach's alpha measured internal consistency. Validity was established using convergent and divergent correlations to other validated scales. A total of 292 participants took part in this study. The 12-item accountability scale demonstrated very good internal consistency (Cronbach's α=0.92). Components of the accountability measurement tool correlated with predicted validated measures, including the Treatment Self-Regulation Questionnaire. Divergent validity was established with no significant difference noted between age, sex, race, and education level. Future use of this questionnaire will allow for the assessment of the interaction between accountability and adherence to treatment and lead to the development of new interventions to promote better adherence.
Sections du résumé
BACKGROUND
BACKGROUND
The accountability inherent in the social interaction between a patient and healthcare provider affects patients' motivation to adhere to treatment. To characterize the role of accountability as a tool to improve self-efficacy and self-management and thereby promote patients' adherence to treatment, a measure of accountability is needed.
AIMS
OBJECTIVE
To develop and test the validity, reliability, and sensitivity of a new outcome measure designed to assess accountability.
METHODS
METHODS
The accountability measurement tool was developed from the literature, expert consultation, and focus groups. A focus group and three pilot studies were performed both in clinic and through an online crowdsourcing platform. Principal Component Analysis evaluated constructs, and Cronbach's alpha measured internal consistency. Validity was established using convergent and divergent correlations to other validated scales.
RESULTS
RESULTS
A total of 292 participants took part in this study. The 12-item accountability scale demonstrated very good internal consistency (Cronbach's α=0.92). Components of the accountability measurement tool correlated with predicted validated measures, including the Treatment Self-Regulation Questionnaire. Divergent validity was established with no significant difference noted between age, sex, race, and education level.
CONCLUSION
CONCLUSIONS
Future use of this questionnaire will allow for the assessment of the interaction between accountability and adherence to treatment and lead to the development of new interventions to promote better adherence.
Identifiants
pubmed: 31564838
doi: 10.2147/PPA.S213113
pii: 213113
pmc: PMC6732501
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1511-1517Informations de copyright
© 2019 Oussedik et al.
Déclaration de conflit d'intérêts
Dr. Feldman is a speaker for Taro, a consultant and speaker for Galderma, Abbvie, Celgene, Abbott Labs, Lilly, Janssen, Novartis Pharmaceuticals and Leo Pharma Inc., has received grants from Galderma, Janssen, Abbott Labs, Abbvie, Celgene, Taro, Sanofi, Celgene, Novartis Pharmaceuticals, Qurient, Pfizer Inc. and Anacor, a consultant for Advance Medical, Caremark, Gerson Lehrman Group, Guidepoint Global, Kikaku, Lilly, Merck & Co Inc, Mylan, Pfizer Inc, Qurient, Sanofi, Sienna, Sun Pharma, Suncare Research, Valeant, and Xenoport, is the founder, chief technology officer and holds stock in Causa Research, holds stock and is majority owner in Medical Quality Enhancement Corporation, and receives royalties from UpToDate, Informa and Xlibris; he reports no other conflicts of interest in this work. Abigail Cline, Lara Kammrath, EJ Masicampo, Elias Oussedik, Jennifer J Su, and Edward Ip have no conflicts of interest to disclose.
Références
Patient Prefer Adherence. 2017 Jul 25;11:1285-1294
pubmed: 28794618
J Clin Psychiatry. 1980 Dec;41(12 Pt 2):21-4
pubmed: 7440521
Arch Dermatol. 2011 Oct;147(10):1223-4
pubmed: 22006146
Psychol Rev. 1977 Mar;84(2):191-215
pubmed: 847061
J Pers Assess. 1985 Feb;49(1):71-5
pubmed: 16367493
J Am Acad Dermatol. 2007 Jul;57(1):81-3
pubmed: 17498841
Front Psychol. 2017 Aug 08;8:1359
pubmed: 28848474
Psychol Bull. 1999 Mar;125(2):255-75
pubmed: 10087938
BMJ. 1997 Feb 22;314(7080):572
pubmed: 9055718
J Drugs Dermatol. 2014 Jul;13(7):833-6
pubmed: 25007367
Psychosom Med. 1999 Jul-Aug;61(4):566-75
pubmed: 10443767
Perspect Psychol Sci. 2011 Jan;6(1):3-5
pubmed: 26162106
J Pers Soc Psychol. 2003 Aug;85(2):348-62
pubmed: 12916575
N Engl J Med. 2003 Jun 26;348(26):2635-45
pubmed: 12826639
Skin Res Technol. 2014 Feb;20(1):62-6
pubmed: 23750992